<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592408</url>
  </required_header>
  <id_info>
    <org_study_id>MenziesSHR</org_study_id>
    <nct_id>NCT02592408</nct_id>
  </id_info>
  <brief_title>A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan</brief_title>
  <acronym>MalTreSu</acronym>
  <official_title>A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to assess the efficacy and safety of the national
      malaria treatment guidelines, asses the efficacy and safety of artesunate and sulphadoxine -
      pyrimethamine (AS+SP) for treatment in uncomplicated P. falciparum and P. vivax malaria and
      the hematologic effect of 14 days routine primaquine based radical cure in patients suffering
      from a P. vivax or mixed infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence of parasitaemia within 42 days of follow in P. falciparum infections</measure>
    <time_frame>In the first 42 days</time_frame>
    <description>Outcome measure is presented unadjusted and adjusted for PCR and compared between P. falciparum intervention and control arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recurrence of parasitaemia within 42 days of follow in P. vivax infections</measure>
    <time_frame>In the first 42 days</time_frame>
    <description>Outcome measure is presented unadjusted and adjusted for PCR and compared between P. vivax intervention and control arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with any parasitemia on day 1, 2 and 3 after treatment</measure>
    <time_frame>on days 1,2,3</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with fever on day 1, 2 and 3 after treatment</measure>
    <time_frame>on days 1, 2, 3</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with gametocytemia on any of the follow up dates</measure>
    <time_frame>In the first 42 days</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with severe anaemia (Hb&lt;7g/dl) or requiring blood transfusion within 42 days of enrolment</measure>
    <time_frame>In the first 42 days</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The fractional change in Hb between baseline and day 7,14 and 16 (incl. proportion of patients with &gt;25% drop in Hb between the time points) in vivax / mixed infection patients receiving PQ</measure>
    <time_frame>on days 0, 7, 14 and 16</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with adverse and serious adverse events</measure>
    <time_frame>In the first 42 days</time_frame>
    <description>Outcome measure is stratified for P. falciparum and P. vivax infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of vivax patients adhering to 14 days of primaquine treatment in the vivax cohort as measured by pill count</measure>
    <time_frame>at the end of 14DPQ treatment (day 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The distribution of G6PD activity among the study population</measure>
    <time_frame>on day of enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Pf: ASP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pv: ASP + 14DPQ on day 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pf: ASP + SDPQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pv: ASP + 14DPQ on day 42</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP</intervention_name>
    <description>3 days of artesunate sulfadoxine/pyrimethamine on days 0-2</description>
    <arm_group_label>Pf: ASP</arm_group_label>
    <arm_group_label>Pv: ASP + 14DPQ on day 2</arm_group_label>
    <arm_group_label>Pf: ASP + SDPQ</arm_group_label>
    <arm_group_label>Pv: ASP + 14DPQ on day 42</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDPQ</intervention_name>
    <description>single dose primaquine on day 2</description>
    <arm_group_label>Pf: ASP + SDPQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14DPQ</intervention_name>
    <description>14 day primaquine starting on day 2</description>
    <arm_group_label>Pv: ASP + 14DPQ on day 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14DPQ on Day 42</intervention_name>
    <description>14 day primaquine starting on day 42</description>
    <arm_group_label>Pv: ASP + 14DPQ on day 42</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 12 months

          -  P. vivax or P. falciparum mono-infection or P. vivax / P. falciparum mixed infection

          -  Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs

          -  Able to tolerate oral medication

          -  Able and willing to comply with the study protocol for the duration of the study

          -  Informed consent from the patient or from a parent or guardian in the case of children

        Exclusion Criteria:

          -  Bodyweight ≤5kg

          -  Presence of general danger signs in children aged under 5 years or signs of severe
             malaria in any patient according to the definitions of WHO

          -  Presence of severe malnutrition

          -  Acute anaemia &lt;8g/dL

          -  Regular medication, which may interfere with antimalarial pharmacokinetics

          -  History of hypersensitivity reactions or contraindications to any of the drug(s)
             tested or used as alternative treatment(s)

          -  A positive pregnancy test or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muzamil Mahdi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Khartoum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Halfa Hospital</name>
      <address>
        <city>New Halfa</city>
        <state>Kassalla</state>
        <zip>31112</zip>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gizeria Slang Hospital</name>
      <address>
        <city>Khartoum</city>
        <zip>11111</zip>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

